SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.110-1.4%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bobbseytwins2001 who wrote (1060)5/31/2025 1:18:14 PM
From: galt3 Recommendations

Recommended By
dorightbythem
JJINV
urslor

   of 1229
 
Just watched a friend lose his business due to convertible debt. Once the covenants are breached, the path to conversion of the debt to equity is swift and unrelenting. Not sure if this is at play here, as PSS surely has the resources to fund without going to such a draconian measure. I continue to believe in Anktiva but wonder how much longer it can take for either significant sales growth or news that the FDA has seen the light. Personally, would be delighted to see a buyout, but doesn't seem to be a good environment right now, given disdain for small biotechs and an FDA that is in turmoil. As my basis is below 3 and my position is very healthy, I'm content, for now, to sit back and watch. Highly doubt I would buy more unless the share price shows significant improvement. Best
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News